Brought to you by 
Roche partners discontinued inclacumab with Global Blood Therapeutics
24 Aug 2018
Executive Summary
Global Blood Therapeutics Inc. (GBT) received exclusive worldwide rights, and sublicensing rights, to develop, manufacture, and commercialize Roche’s preclinical fully human monoclonal antibody inclacumab against P-selectin, a target in sickle cell disease. The deal also includes patent rights and know-how, as well as modified compounds derived from inclacumab and interacting with P-selectin. Concurrent with the present agreement, GBT licensed Roche nonexclusive global and royalty-free rights to inclacumab for diagnostics uses.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche partners discontinued inclacumab with Global Blood Therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice